Discussing Vertex Pharmaceuticals’ RAINIER's Phase 3 Trial Results of Povetacicept in IgA Nephropathy & Primary Membranous Nephropathy

Executed on:Mar 31, 2026 1:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: University of Southern CaliforniaAssociate Professor of Medicine at Keck-USC School of Medicine & Medical Director of the CKD program and the Renal, Hypertension and Transplant Clinic at the LAC+USC. 
Treats 190 patients with IgA nephropathy or primary membranous nephropathy and patients with both HRS1 and HRS2 and over 200 patients with Anemia-CKD.
Research focuses on advancing kidney dialysis, liver dialysis and providing a support system for the MOF/MODS multisystem failures; has been actively conducting major pharmaceutical sponsored phase II-IV clinical trials in hypertension, anemia, iron, and secondary hyperparathyroidism.

Interview Goal

To gain a deeper understanding of Vertex Pharmaceuticals’ Povetacicept as a potential treatment in IgA Nephropathy & Primary Membranous Nephropathy. Examining how it compares to Tarpeyo, Filspari, Fabhalta, Vanrafia and Voyxact 

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.